Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Sensyne Health continues to strengthen its management team with two further senior appointments

February 5, 2021

Oxford, U.K. 5 February 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company’s global product for value-based care and previously its global product proposition in the women’s health space. Prior to that, Hina founded the UK’s first virtual care platform for women’s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte. At Sensyne, Hina will lead the Company’s focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne’s pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne’s excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years.”  

Press release

Sensyne Health continues to strengthen its management team with two further senior appointments

February 5, 2021

Oxford, U.K. 5 February 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company’s global product for value-based care and previously its global product proposition in the women’s health space. Prior to that, Hina founded the UK’s first virtual care platform for women’s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte. At Sensyne, Hina will lead the Company’s focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne’s pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne’s excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years.”  

Press release

Sensyne Health continues to strengthen its management team with two further senior appointments

Sensyne Health continues to strengthen its management team with two further senior appointments

February 5, 2021

Oxford, U.K. 5 February 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company’s global product for value-based care and previously its global product proposition in the women’s health space. Prior to that, Hina founded the UK’s first virtual care platform for women’s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte. At Sensyne, Hina will lead the Company’s focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne’s pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne’s excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years.”  

Press release

Sensyne Health continues to strengthen its management team with two further senior appointments

Sensyne Health continues to strengthen its management team with two further senior appointments

Oxford, U.K. 5 February 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company’s global product for value-based care and previously its global product proposition in the women’s health space. Prior to that, Hina founded the UK’s first virtual care platform for women’s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte. At Sensyne, Hina will lead the Company’s focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne’s pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne’s excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years.”  

Arrange to meet us
Press release

Sensyne Health continues to strengthen its management team with two further senior appointments

February 5, 2021

Oxford, U.K. 5 February 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division.

Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company’s global product for value-based care and previously its global product proposition in the women’s health space. Prior to that, Hina founded the UK’s first virtual care platform for women’s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte. At Sensyne, Hina will lead the Company’s focus on the commercialisation of its clinical AI software for remote patient monitoring and decision-making support.

Martin Gouldstone is a 30-year life-sciences veteran in business development and corporate finance with deep experience in sourcing and closing major strategic collaborations in both the digital health and pharmaceutical industries. He joins Sensyne on 01 March from Syneos where he was Global SVP Capital Solutions at Syneos One and has held senior positions at BenevolentAI, as Chief Business Officer, BDO as Head of Life Sciences in the UK, Results Healthcare, as a partner and co-lead of its healthcare practice and Quintiles where Martin led M&A in Europe. As CBO of Life Sciences at Sensyne, Martin will be responsible for expanding and growing Sensyne’s pharmaceutical industry partnerships, focused both on organic growth and new strategic M&A opportunities that build shareholder value.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted to welcome Hina and Martin to Sensyne.  They bring deep experience and strong personal networks that further strengthen Sensyne’s excellent leadership team and increase our capacity to manage the significant growth we expect to deliver over the coming years.”